Podcasts about Moca

#crawfordvscanelo #nymets #bsnf ¡Conéctate, comenta y comparte! Más De Una Milla 16/09/2025 Terence Crawford y Canelo Alvarez brindaron una gran noche para el boxeo que estaba necesitado de una | Stephanie Piñeiro obtuvo el título interino de la Asociación Mundial de Boxeo de las 147 libras en Bayamón | Las Explosivas de Moca asumen el liderato del Baloncesto Superior Nacional Femenino | Los Mets de Nueva York podrían quedarse afuera de la postemporada si mantienen la mala racha de derrotas en Grandes Ligas | La lluvia no ha permitido que la temporada de las Taínas de Utuado arranque de lleno en el Béisbol Superior Doble A Femenino #VamoArriba #AlmuerzoDeportivo #tiempodedeportes #BonitaDeportes #DeporteEsMásQueJuego #Anótalo #periodismoinvestigativo #PeriodismoDigital #Comparte #PonloEnLaNevera #BSNF #CaneloVsCrawford #Boxeo #ClasicosDelBoxeo #BéisbolDobleAFemenino #StephaniePiñeiro #metsnuevayork #GrandesLigas ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

#aguapalosgallos #bsnf #canelovscrawford Ernesto Díaz González dejó una enorme huella en el deporte puertorriqueño | Las Explosivas de Moca son la líderes del Baloncesto Superior Nacional Femenino | Adriana Díaz jugará contra la mejor tenismesista del mundo, Sun Yingsha | TYodo listo para la esperada pelea entre Saúl "Canelo" Álvarez y Terrence "Bud" Crawford | Selección U18 de béisbol juega para 1-1 en la Super Ronda del Mundial en Okinawa ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

#AdrianaDíaz #canelovscrawford bsnf Adriana Díaz obtuvo una de las más importantes triunfos en su carrera al derrotar a Wang Yidi, 5ta sembrada del mundo, en el WTT Champions en Macao | Las Atenienses de Manatí y Explosivas de Moca obtuvieron victorias en el BSNF | Canelo vs Crawford tiene todos los ingredientes para ser una pelea memorable. #VamoArriba #AlmuerzoDeportivo #tiempodedeportes #BonitaDeportes #DeporteEsMásQueJuego #Anótalo #periodismoinvestigativo #PeriodismoDigital #Comparte #PonloEnLaNevera #BSNF #AdrianaDíaz #CaneloVsCrawford #Boxeo #ClásicosDelBoxeo ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

Welcome to the Part Time Pilot Audio Ground School Podcast! This podcast takes our free podcast to a whole new level by providing students with every single lesson included in the Part Time Pilot Private Pilot & IFR Ground Schools without a single Ad! On top of that, VIP podcast students get BONUS episodes like Mock Checkrides, Checkride Prep, Expert Interviews and more!   The #1 reason student pilots never end up becoming a private pilot is NOT due to money. The real reason is actually deeper than that. Yes, flight training is expensive. But every student pilot knows this and budgets for it when they decide to do it.   The actual #1 reason a student pilot fails is because they do not have a good, fundamental understanding of the private pilot knowledge they are meant to learn in ground school.   You see when a student does not have a good grasp of this knowledge they get to a point in their flight training where their mind just can't keep up. They start making mistakes and having to redo lessons. And THAT is when it starts getting too expensive.   This audio ground school is meant for the modern day student pilot... aka the part time student pilot. Let's face it, the majority of us have full time responsibilities on top of flight training. Whether it is a job, kids, family, school, etc. we all keep ourselves busy with the things that are important to us. And with today's economy we have to maintain that job just to pay for the training. The modern day student pilot is busy, on the go and always trying to find time throughout his or her day to stay up on their studies. The audio ground school allows them to consume high quality content while walking, running, working out, sitting in traffic, traveling, or even just a break from the boring FAR/AIM or ground school lecture.   Did I meant high quality content? The audio ground school is taken straight out of the 5-star rated Part Time Pilot Online Ground School that has had over 2000 students take and pass their Private Pilot & IFR exams with only 2 total students failing the written. That's a 99.9% success rate! And the 2 that failed? We refunded their cost of ground school and helped them pass on their second attempt. We do this by keeping ground school engaging, fun, light and consumable. We have written lessons, videos, audio lessons, live video lessons, community chats, quizzes, practice tests, flash cards, study guides, eBooks and much more.   Part Time Pilot was created to be a breath of fresh air for student pilots. To be that flight training provider that looks out for them and their needs. So that is just what we are doing with this podcast.     IFR Section 5 Lesson 6: In this FREE Online Ground School lesson for IFR we are going to talk about IFR Airway Altitudes. So far, we have just briefly mentioned the definitions of altitudes such as the MEA or the MOCA. Well, there are more altitudes we need to know and we need to dive deeper into what they are and how IFR pilots will use them in IFR Flight Plans.    Links mentioned in the episode:   IFR Airway Altitudes Video: https://youtu.be/UcmBlcYVloM    Private Pilot Online Ground School: PPL Ground School - Part Time Pilot Checkride Prep: PPL Checkride Prep - Part Time Pilot IFR Online Ground School: IFR Ground School – Part Time Pilot   PPL study group: https://www.facebook.com/groups/parttimepilot  IFR study group: https://www.facebook.com/groups/parttimepilotifr/   Recommended Products & Discounts:  https://parttimepilot.com/recommended-products-for-student-pilots/ 

Jon Jordan and Jenny Jordan talk through the week's news including:[1:18] Looking at the most popular blockchain games, we can start to see some trends for 2025. [1:42] Axie Infinity and Aliens Worlds have been very stable throughout 2025.[4:17] Games such as Pixels and Nine Chronicles have decline sharply as they rethink their vision.[6:00] MapleStory Universe is the big growth story of the year so far - c. 70,000 DAUWs.[8:41] Craft World has launched its first mainnet collab with Ronkeverse.[15:16] Gigaverse has raised $2.3 million to build out open world gameplay.[16:55] We're seeing a rise of degen-focused onchain games. Niche but generating revenue.[20:42] LOL Land is a good example. It's basically an onchain lottery but generated $1.5 million.[22:15] Similar are RWA platforms for Pokemon cards like Courtyard. $125 million of trading in August.[27:10] Animoca has announced MocaPortfolio, which will be rewarding $20 million to stakers.[28:43] This is part of a wider narrative for Animoca to boost the MOCA token around a possible IPO.[32:33] Stakers will burn their staked points to get various free tokens. The first is Magic Eden's ME. [34:01] How is Mythical Games doing with its three mobile games now live?[35:06] This is in contrast to the trend towards more niche, onchain degen-focused games.

#JCQ #BSNF #PulpoRivera Más De Una Milla 04/09/2025 Jasmine Camacho Quinn se retiró del Mundial de Atletismo por una lesión | Las Gigantes de Carolina acabaron con las Explosivas de Moca a fuerza de triples; las Cafetaleras de Yauco lucieron fantásticas en la victoria sobre las Leonas de Ponce | Emmanuel “El Pulpo” Rivera produce en grande para los Orioles a siete días de regresar al equipo grande | Todo listo para el comienzo del Mundial U18 de béisbol en Okinawa, Japón #VamoArriba #AlmuerzoDeportivo #tiempodedeportes #BonitaDeportes #DeporteEsMásQueJuego #Anótalo #periodismoinvestigativo #PeriodismoDigital #Comparte #PonloEnLaNevera #BSNF #wbsc #Béisbol #jóvenes #PulpoRivera #JasmineCamachoQuinn ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

#JCQ #BSNF #PulpoRivera Más De Una Milla 04/09/2025 Jasmine Camacho Quinn se retiró del Mundial de Atletismo por una lesión | Las Gigantes de Carolina acabaron con las Explosivas de Moca a fuerza de triples; las Cafetaleras de Yauco lucieron fantásticas en la victoria sobre las Leonas de Ponce | Emmanuel “El Pulpo” Rivera produce en grande para los Orioles a siete días de regresar al equipo grande | Todo listo para el comienzo del Mundial U18 de béisbol en Okinawa, Japón #VamoArriba #AlmuerzoDeportivo #tiempodedeportes #BonitaDeportes #DeporteEsMásQueJuego #Anótalo #periodismoinvestigativo #PeriodismoDigital #Comparte #PonloEnLaNevera #BSNF #wbsc #Béisbol #jóvenes #PulpoRivera #JasmineCamachoQuinn ¡Conéctate, comenta y comparte! #periodismoindependiente #periodismodigital #periodismoinvestigativo tiktok.com: @bonitaradio Facebook: bonitaradio Instagram: bonitaradio X: Bonita_Radio

Join us for an exciting episode of The Alexei ZamyatinEdge of Show, live from ECC 8 in Cannes! In this episode, Tom Vieira from Coinbase explores how Coinbase is approaching on-chain identity and infrastructure, and why developer experience is at the heart of crypto's next growth cycle. Next Alexei Zamyatin from BOB breaks down Bitcoin-secured rollups, explaining how BOB is merging the strengths of Bitcoin and Ethereum to create a hybrid ecosystem and finally Kenneth Shek from Moca Network shares how Museum of Crypto Art is evolving as a cultural hub, curating digital art and expanding the role of creators in the decentralized era.Don't miss this insightful conversation packed with expert perspectives on the future of Bitcoin, DeFi, and the broader crypto ecosystem!Support us through our Sponsors! ☕

Dos presuntos reconocidos delincuentes, implicados en el rapto y posterior asesinato de un taxista en Moca, cayeron abatidos en un alegado enfrentamiento a tiros con agentes de la Policía Nacional, en un altercado registrado en la comunidad La Estancia, en Las Matas de Farfán.

For episode 570 of the BlockHash Podcast, host Brandon Zemp is joined by Kenneth Shek, the Project Lead of Animoca Brands' Moca Network, which is building a decentralized digital identity infrastructure that unifies identity, assets and data across platforms.  ⏳ Timestamps: (0:00) Introduction(0:36) Who is Kenneth Shek?(1:22) What is Moca Network?(3:45) Digital ID & Credentials(5:50) Moca Use-cases(9:20) Types of identity onchain(11:30) Moca Network at Permissionless(13:11) Moca Network website, socials & community(13:44) RAPID FIRE SESSION

Today's podcast mines the nitty-gritty of the entire AI revolution —from its economics, to its decentralized use-case, to the way data centers operate, and more— with two of the best quarrymen in the business. MOCA Chief Technology Officer joins Max, and both welcome Founder and CEO of Comput3AI, Nedos, to fill in every possible blank about the world's most important industry. This is a conversation between technical heavyweights (and Max), and surely an episode of MOCA LIVE not to be missed.

Can Alzheimer's disease be reversed or at least significantly improved?In this powerful interview, Dr. Heather Sandison, a leading expert in dementia prevention and the author of Reversing Alzheimer's, shares what she's learned helping patients dramatically improve memory, regain function, and slow cognitive decline.You'll learn:-How to reverse early Alzheimer's symptoms?-The real causes of Alzheimer's disease-How to prevent Alzheimer's disease-How toxins, insulin resistance, and stress trigger dementia-What tests you should consider to assess your brain health?-The supplements and daily habits that make the biggest difference✨ Resources:Dr. Heather Sandison's website: https://drheathersandison.comHer book Reversing Alzheimer's: https://www.drheathersandison.com/reversing-alzheimers-book/

A primeira versão deste episódio era hilariante. Fiquem com a segunda melhor versão. Curti de gravar este, mesmo que à segunda, por isso se me puderem dar five stars ou um magnum de amêndoa, ficaria muito grato. beijinhos a todes.BILHETES BLISS - https://tr.ee/BTFhU5kclmLinks homeopáticos -⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/joaonunogoncalo⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sem preciosas perguntas

Urs Fischer is a contemporary artist renowned for his experimental and highly unpredictable practice of sculpture, installation, painting, and photography. He often uses unconventional materials, such as wax, bread, and everyday objects, which he employs to explore themes of transformation, impermanence, and creative destruction, allowing his works to transform or decay over time. Fischer's work, influenced by movements like Surrealism and Pop Art, is marked by a dynamic interplay between construction and deconstruction, permanence and ephemerality, inviting audiences to reconsider the boundaries of art and the fleeting nature of existence. Fischer has held major solo exhibitions at institutions such as Kunsthaus Zürich, the New Museum in New York, Palazzo Grassi in Venice, MOCA in Los Angeles, and galleries including Sadie Coles HQ in London and Gagosian locations worldwide—most recently at Gagosian Gstaad in Switzerland. ------ Thank you to the sponsors that fuel our podcast and our team: LMNT Electrolytes https://drinklmnt.com/tetra Use code 'TETRA' ------ Athletic Nicotine https://www.athleticnicotine.com/tetra Use code 'TETRA' ------ Squarespace https://squarespace.com/tetra Use code 'TETRA' ------ Sign up to receive Tetragrammaton Transmissions https://www.tetragrammaton.com/join-newsletter

Zumbido & Cognição no Idoso, o que todo geriatra precisa saber. Neste episódio, analisamos as evidências mais recentes que ligam o tinnitus crônico a déficits de atenção, memória e funções executivas, discutimos o risco de comprometimento cognitivo leve / demência e detalhamos um protocolo de avaliação e manejo integrado (audiometria, THI, MoCA, TCC, reabilitação auditiva). Você sai com passos práticos para rastrear e tratar zumbido visando preservar a função cognitiva do seu paciente idoso. Aperte o play e atualize sua conduta! Assine o GeriUpdates https://www.gericlass.com.br/op/geriupdates//

1.  ¿Qué negoció el PNP con los ferales en este caso de Wanda Vázquez? Sí ella se declara culpable, y sí es la primera exgobernadora culpable, pero seguirá tranquila recibiendo su pensión. Aquí la pregunta es ¿por qué las autoridades federales no se mueven? ¿Han negociado algo con el PNP que no apresan a nadie desde Tata Charbonnier? ¿Cuál es el verdadero impacto del acuerdo de la exgobernadora?, lo converso con el periodista, abogado y editor, Daniel Nina, de El Post Antillano.2.  También hablamos con Nina sobre lo que sucede entre Israel e Irán, el genocidio en Palestina y Trump3.  Designan a un FEI para investigar al exalcalde de Moca por presunta propaganda política ilegal4.  El DSP asegura que saldará en junio deuda de $32 millones en horas extras a policías5.  Trump se marcha de la cumbre del G-7 por la tensión en Oriente Próximo6.  El republicano insta a evacuar Teherán, tras negarse a una declaración de la cumbre sobre Oriente Próximo7.  El autor de los atentados de Minnesota acudió esa noche a casa de otros dos congresistasEste es un programa independiente y sindicalizado. Esto significa que este programa se produce de manera independiente, pero se transmite de manera sindicalizada, o sea, por las emisoras y cadenas de radio que son más fuertes en sus respectivas regiones. También se transmite por sus plataformas digitales, aplicaciones para dispositivos móviles y redes sociales. Estas emisoras de radio son:1.    Cadena WIAC - WYAC 930 AM Cabo Rojo- Mayagüez2.    Cadena WIAC – WISA 1390 AM Isabela3.    Cadena WIAC – WIAC 740 AM Área norte y zona metropolitana4.    WLRP 1460 AM Radio Raíces La voz del Pepino en San Sebastián5.    X61 – 610 AM en Patillas6.    X61 – 94.3 FM Patillas y todo el sureste7.    WPAB 550 AM - Ponce8.    ECO 93.1 FM – En todo Puerto Rico9.    WOQI 1020 AM – Radio Casa Pueblo desde Adjuntas10. Mundo Latino PR.com, la emisora web de música tropical y comentario Una vez sale del aire, el programa queda grabado y está disponible en las plataformas de podcasts tales como Spotify, Soundcloud, Apple Podcasts, Google Podcasts y otras plataformas https://anchor.fm/sandrarodriguezcotto También nos pueden seguir en:REDES SOCIALES:  Facebook, X (Twitter), Instagram, Threads, LinkedIn, Tumblr, TikTok BLOG:  En Blanco y Negro con Sandra http://enblancoynegromedia.blogspot.com  SUSCRIPCIÓN:Substack, plataforma de suscripción de prensa independientehttps://substack.com/@sandrarodriguezcotto OTROS MEDIOS DIGITALES: ¡Ey! Boricua, Revista Seguros. Revista Crónicas y otrosEstas son algunas de las noticias que tenemos hoy En Blanco y Negro con Sandra. 

A little performance art, a couple of classic Los Angeles locations, happy birthday to my mom, a unforgettable glowing suitcase, a classic Los Angeles evangelist, our imperfect memories, a Matthew Perry moment, one (and I mean one) moment of insight from Trump, a mea culpa to Jai Courtney, Paul Dano still sucks, and c'mon and join our convoy. Stuff mentioned: Nadya Tolokonnikova POLICE STATE (WAREHOUSE at the Geffen Contemporary at MOCA, 152 N Central Ave, Los Angeles, CA 90012 https://www.moca.org/program/nadya-tolokonnikova-police-state), Bradbury Building (304 S Broadway, Los Angeles, CA 90013), Double Indemnity (1945), Chinatown (1974), Wolf (1994), Blade Runner (1982), Newhart (1982-1990), Angels Flight Railway (351 S Hill St, Los Angeles, CA 90013), Hill Street Blues (1981-1987), Criss Cross (1949), Kiss Me Deadly (1955), Generation X "Kiss Me Deadly" (1981), Generation X Kiss Me Deadly (1981), Pulp Fiction (1994), Repo Man (1984), Raiders of the Lost Ark (1981), Highway Patrolman (1991), La La Land (2016), Perry Mason (2020-2023), Orphan Black (2013-2017), Angelus Temple (1100 Glendale Blvd, Los Angeles, CA 90026),  Claire Hoffman Sister, Sinner: The Miraculous Life and Mysterious Disappearance of Aimee Semple McPherson (2025), Pavement Slanted and Enchanted (1992), Matt Bai The Unbearable lightness of Elon Musk (The Washington Post, June 1, 2025 https://www.washingtonpost.com/opinions/2025/06/01/musk-doge-defeat-washington-bureaucracy), A Good Day to Die Hard (2013), Terminator Genisys (2015), Die Hard (1988), Dangerous Animals (2025), The Loved Ones (2009), The Devil's Candy (2015), Dead Calm (1989), and C.W. McCall "Convoy" (1975).

A lengthy conversation between THORChain, Rujira and Moca contributors regarding the potential of XRP being available on a DEX for the first time.

Matteo Moca"Un paniere di chiocciole"Tommaso LandolfiAdelphiwww.adelphi.itCinquanta elzeviri: ovvero cinquanta micidiali congegni capaci di incrinare ogni certezza.Costretto a lavorare su un minuscolo scrittoio, il protagonista di A tavolino realizza che lo spazio è insufficiente «a qualunque libera espansione dell'intelletto» e che la redazione di testi «eterni e feraci» gli è ormai preclusa. Eppure, ribadisce a sé stesso, «ho da fare un articolo, e se non lo faccio i miei figlioletti rimangono desolati, famelici...». Così, con feroce autoironia, Landolfi mette in scena la sua condizione di elzevirista al soldo del «Corriere della Sera» e un'idea di letteratura sfrondata di ogni alloro, prigioniera di una gabbia coercitiva, ridotta alla funzione di gagne-pain. Ma proprio nel loro carattere di scrittura ricondotta alla sua chimica essenza risiede il fascino di questi cinquanta elzeviri, perfetti congegni capaci di evocare incontri mancati, occasioni ignorate perché «il gelido soffio della disperazione» spazza via ogni speranza; di vivisezionare relazioni di coppia oblique, simili ad acerbi duelli o a una «benigna trama di nulla»; di rivelare, con la gelida efficacia dell'incubo, l'inconsistenza di ciò che chiamiamo «io», di vanificare la fiducia nella ragione, di dar corpo alle nostre più segrete paure: nello splendido Il bacio, per esempio, l'invisibile creatura che ogni notte visita, imprimendogli un bacio sulle labbra, un timido e al principio deliziato notaio si rivela una falla «nel nero etere cosmico», decisa a succhiargli la vita. Un incubo è del resto il nostro vivere quotidiano, assediato dal bisogno, dal vuoto, da un angoscioso «senso d'irrealtà, di casualità» – dalla tragica consapevolezza che «la gente, quando non è noi, è odiabile perché non è noi; quando è noi, è odiabile perché è noi».Matteo Moca è nato a Popoli nel 1990. Ha studiato italianistica a Bologna e a Parigi e fa l'insegnante in provincia di Pistoia. Ha scritto il saggio Un'esigenza di realtà. Anna Maria Ortese e la dipendenza dal fantastico (LiberAria 2022) e si è occupato di Tommaso Landolfi, Georges Perec, Alberto Savinio e Antonio Delfini, e della convergenza tra letteratura, psicoanalisi e arti figurative. Collabora con «Domani», «Il Foglio», «Il Tascabile» e «Blow Up»."Una consunzione infinita" è il nuovo libro, pubblicato da ItaloSvevo.IL POSTO DELLE PAROLEascoltare fa pensarewww.ilpostodelleparole.itDiventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.

Trifulca Media Presenta:La Pandemia Urbana Con, Alex Torres y Omar Vázquez quienes entrevistan al cantante Puertorriqueño nacido en Moca, quien esta dando sus pasos en la Música Urbana. Nos habla de sus nuevos temas #NombreyApellido y #BuenosDías . Sigan a Kenny https://www.facebook.com/share/16iveRoGpb/?mibextid=wwXIfrhttps://www.instagram.com/kennyyofficial?igsh=ZnIyeDV3dmNqaG0wTienda De La Trifulca - La TrifulcaFacebook - https://ppppppppppppppQ XS www.facebook.com/a TrifulcaMedia?mibextid=LQQJ4d .p opiokcInstagram - https://www.instagram.com/latrifulcamedia?igsh=MW1yNGE2NnY0N2pyYw==Threads - https://www.threads.net/@latrifulcamediaYouTube - https://youtube.com/@trifulcamedia?si=Spotify - https://open.spotify.com/show/2Nki4huLPMwYftru08gFYV?si=Z2AMDLjRSiOc2U_LVUXRpwApple Podcast - https://podcasts.apple.com/us/podcast/trifulca-media/id1459553025#kennyy#BuenosDías #NombreyApellido #musicaurbana #reggaeton #jaywheeler#lapandemiaurbana #podcast#pr#trifulcamedia

Andres del Vecchio and Anubis3100, besides being unbelievable craftsmen and artists, are brilliant critics, crypto art sages. These two join Max to discuss Andres' "DYBBUK MASQUES," a series of 1/1/x works that might very well portend a change in crypto art's very market dynamics. Or it could just be a marker of Andres' unique talents. "Artist-led PFPs" redefined, connecting with collectors, the appeal of digital avatars, and much more await you in today's episode.

Episode 475 / Banks VioletteBanks Violette is an artist born in Ithaca, NY who lives and works in Ithaca, NY. He recieved his BFA from the School of Visual Arts  and an MFA from Columbia University. He's had numerous solo shows including ones at MoCa, Connecticut, Gladstone Gallery, Blum & Poe, Thaddeus Ropac, Maureen Paley, Team Gallery, Rodolphe Janssen, and the Whitney Museum to name just a few. He's had scores of group shows all over the globe from the Museum of Modern Art to the Warhol Museum and his work is in the collections of The Coppel Foundation, MexicoThe Ellipse Foundation, Portugal, The Centre Pompidou, Paris, France, Frank Cohen Collection, Manchester, England The Jumex Foundation, Mexico, Los Angeles County Museum of Art, Los Angeles, Migros Museum für Gegenwartskunst, Zurich, Switzerland Musée d'Art Moderne et Contemporain, Geneva, Switzerland Museum of Contemporary Art, Los Angeles, Museum of Modern Art, New York, The OverHolland Collection, Amsterdam, The Netherlands The Saatchi Collection, London, UK, The Solomon R. Guggenheim Museum, New York, Frederick R. Weisman Art Foundation, Los Angeles and the Whitney Museum of American Art, New York. 

Tune in to today's episode as we are diving back into the world of cryptozoology with a classic cryptid - and that my friends is none other than El Chupacabra(s). In this episode we'll get into the origins of this strange creature taking a look at the Puerto Rico sightings of the mid-90s as well as some other mysterious encounters including the Moca Vampire. We'll also look at how the myths and tales evolved over time and if there are any viable theories as to what was terrorizing the island of Puerto Rico all those years ago. Was it an alien? a dog/coyote hybrid? a government experiment gone wrong? or perhaps a demon? tune in to find out... All of this and more in this episode! Music Credit: Clyde Lewis - El Chupacabra Song

In the dark, away from attention, the metaverse grows, thrives even, with the introduction and assistance of AI. AI agents peopling metaverse worlds. AI-generated avatars. But one of the most interesting possibilities of an AI-integrated metaverse is AI architecture, not just for the speed with which virtual 3D structures can be created but the newfound intricacy. It's an entirely new avenue for artistry, both in 3D worlds, and also full-stop, a new frontier. Today, Colborn and Max talk with MOCA's resident Metaverse architect, Untitled,XYZ about UnMuseums,  a collection of AI-generated architectures and his final flourish for MOCA ROOMs. The nitty-gritty of process, conception, outcome, and consequence, expect all of that and more on today's episode of MOCA LIVE.

This episode explores the trends, secrets, and future of luxury and high-street retail in Los Angeles and beyond with Jay Luchs, Vice Chairman of Newmark.The Crexi Podcast explores various aspects of the commercial real estate industry in conversation with top CRE professionals. In each episode, we feature different guests to tap into their wealth of CRE expertise and explore the latest trends and updates from the world of commercial real estate.  In this episode, Shanti Ryle, Director of Content Marketing at Crexi, sits down with Jay, one of Los Angeles's most prominent retail commercial real estate brokers. They discuss Jay's background, his journey from aspiring actor to leading real estate broker, and his significant transactions, including deals with top global fashion brands and high-profile real estate deals along Rodeo Drive and Melrose Avenue. Jay shares insights into the world of luxury retail, the challenges and strategies in securing prime retail locations, and the importance of genuine connections and caring about the community's landscape. They also explore the impact of social media on retail, the dynamics of leasing and buying in high-demand areas, and Jay's perspective on the future of retail in Los Angeles.Introduction and Guest WelcomeJay Luxe's Background and Career HighlightsEarly Career and Transition to Real EstateChallenges and Strategies in Real EstateSpecialization in Retail LeasingNotable Deals and Community ImpactLuxury Retail and Market InsightsUnderstanding Real Estate PricingLocation and Rent DynamicsChallenges in Leasing and Landlord-Tenant RelationshipsImportance of Taxes and Broker RepresentationRetail Landscape and Market TrendsRestaurant Real Estate DynamicsFuture of Retail and Real Estate InsightsRapid Fire Questions and Closing Thoughts About Jay Luchs:Jay Luchs is Vice Chairman at Newmark and one of Los Angeles' most recognizable commercial real estate brokers, known for his “For Lease” and “Leased” signs across the city. He specializes in retail, office, and investment sales, representing top global fashion brands, entertainment companies, and emerging retailers. Luchs has completed major transactions for clients such as LVMH, Louis Vuitton, Dior, Celine, KITH, James Perse, and Equinox, including high-profile deals along Rodeo Drive, Melrose Avenue, and Sunset Boulevard.He played a key role in LVMH's $200 million purchase of the Luxe Hotel and the $122 million sale of 457-459 N Rodeo Drive to the Rueben Brothers. He's also helped launch first stores for brands like Alo Yoga and James Perse, and secured pop-up and permanent spaces for brands like Supreme, SKIMS, and Fear of God.In addition to retail, Luchs places corporate offices for fashion and entertainment clients, including Tom Ford, H&M, STAUD, and Brunel cuccinelli and various lvmh offices. He's also active in the local art and restaurant scenes, helping galleries like Gagosian and restaurants such as Craig's, Avra, and Tao Group find key locations across LA.Luchs and his team represent over 125 landlord listings in premier areas such as Rodeo Drive, Abbot Kinney, and Malibu. A top producer at Newmark since 2014, he has closed several billion dollars in deals. Originally from Maryland, Luchs graduated from the University of Virginia and has lived in Los Angeles since 1995. He serves on MOCA's Acquisition and Collections Committee. If you enjoyed this episode, please subscribe to our newsletter and enjoy the next podcast delivered straight to your inbox. For show notes, past guests, and more CRE content, please check out Crexi's blog. Ready to find your next CRE property? Visit Crexi and immediately browse 500,000+ available commercial properties for sale and lease. Follow Crexi:https://www.crexi.com/​ https://www.crexi.com/instagram​ https://www.crexi.com/facebook​ https://www.crexi.com/twitter​ https://www.crexi.com/linkedin​ https://www.youtube.com/crexi

In this enlightening episode, we engage in an in-depth discussion with Melissa Gainey, the esteemed founder of In The Garden Counseling, LLC, located in Lexington, South Carolina. As a Licensed Professional Counselor, Melissa brings a wealth of experience to the table, including cognitive behavioral therapy, a topic of growing relevance in our society. The conversation delves into the nuances of cognitive assessments, including a notable test administered to President Donald Trump, which Melissa graciously conducts on our host, Barrett Gruber. We explore the multifaceted nature of cognitive health, touching upon its implications for aging individuals and their families, as well as the broader societal context. Ultimately, this dialogue aims to illuminate the critical importance of mental health awareness and the resources available to those navigating these challenges.Make sure to check out ZJZ Designs Visit In The Garden Counseling LLC for a list of Melissa's Services.MoCA 8.3 English Test (pdf)Montreal Cognitive AssessmentIn The Garden Counseling LLC - Counseling in Lexington, SCClick here for Episode Show Notes!Click Here to see available advertising packages!Click Here for information on the "Fair Use Copyright Notice" for this podcast.Mentioned in this episode:BIG Media LLC Copyright 2025This Podcast is a product of BIG Media LLC and Copyright 2025 Visit https://barrettgruber.com for more from BIG Media LLC!BIG Media LLCEverplay Sports and Social LeagueSummer Sports are registering through May 21st, 2025! Visit https://everplaysports.com Music from #Uppbeat (free for Creators!): https://uppbeat.io/t/trinity/all-stars-show License code: O9PSCKXIEBKXKSRYEverplay Sports & Social League

Jose Duran (b. 1979, Moca, Dominican Republic) is a painter, designer, and sculptor creating fantastical worlds of cosmopolitan opulence and sumptuous, even dangerous foliage. Duran's practice is anchored in extensive research of practices of survival, celebration, vengeance, sabotage, and aspirational desires in Black communities. He draws from baroque and rococo interiors to create scenes of architectural lavishness and femininity, producing complex compositions anchored in whimsy and play. Duran centers Black feminine figures as a reclamation of their contributions to European markers of taste, and as retribution for their forced labor under colonial rule. Duran's fantasies retrospectively place Black women at the center of his lavish interiors, where they reap the fruits of their labor. His practice is an ode to the dreams and aspirations of his late mother, who, between the Bronx and the Dominican Republic, would imbue in the artist a taste for cosmopolitanism and beauty. Photo credit: Nelson Castillo Artist https://joseduran.studio/ Hannah Traore Gallery https://hannahtraoregallery.com/exhibition/aleluya/ James Fuentes https://jamesfuentes.com/exhibitions/elena NY Times https://www.nytimes.com/2024/05/10/style/roze-traore-hannah-traore-gallery.html Art Speak https://www.artspeak.nyc/home/2024/2/13/jose-duran Island Origins Magazine https://islandoriginsmag.com/dominican-artist-jose-duran-aleluya/ Arthap https://arthap.com/hap/opening-jose-duran-aleluya/ Idiom Studio https://idiomastudio.com/jose-duran-caught-between-fantasy-reality/

«Hacía ocho años que tenía en jaque a todo el Cibao. Se presentaba de improviso en Santiago, desaparecía y al otro día abaleaba un soldado en Salcedo.... Se dijo que era brujo; que cuando lo quería, se hacía invisible. Se le temía como a un dios implacable. El Gobierno despachó cientos de hombres tras él, y el ejército llenaba la cárcel de pobres campesinos, sospechosos de encubrirle. Nada.... »... Me llenó de sorpresa verlo tan sereno... como si no fuera el objeto de una caza feroz y larga. Llevaríamos más de media hora allí. Él había contado innumerables episodios de su vida y parecía muy cansado. Tenía una voz triste.... Él era campesino, joven.... »—Quique. Quizá yo pueda serle útil sin faltarle a mi conciencia. »—No, amigo, no tiene que faltarle; sólo lo quería pa conversar con usté. Me parece que no voy a durar mucho, y como de mí se habla tanto, no quería morirme sin que siquiera un hombre supiera que de no acosarme como un perro con rabia, esto se hubiera evitao.... »... Torné a verlo. Ni miraba ni se movía. Negro, triste y perseguido... »—No piense mal, Quique. ¿Por qué va a morirse usté? »—Es que tengo que morirme, amigo.... He pasao muchos años poniéndole el frente al diablo y llevándome en claro a muchos vagamundos; pero hace unos quince días que me pasó una cosa muy mala, y dende entonces ni an duermo.... Quique había estado rondando por Licey en pos de un compadre enfermo, y los soldados lo velaron. Ellos no acertaban nunca, porque la fama de Quique les hacía temblar el pulso a los mejores. Además, no se cuidaban de que hubiera o no gente. Mejor si la había, porque así se propalaba la noticia de que se había enfrentado al temible Quique Blanco, y eso, claro, podía proporcionar algún ascenso. Así, ese día una niña cruzaba cerca del fuego. La cogió una bala de Quique. Él la vio caer, y de golpe sintió que se le aflojaba el corazón. »—Dende ese día ando como loco, amigo. Cierro los ojos y la veo cayendo. Era una pobre criatura. No me lo perdono, amigo, y quisiera tener el poder de Dios pa devolvérsela a su mama.... »—¿Usté tiene hijos, Quique? —pregunté. »—No, amigo. Si hubiera tenío uno... »Adiviné el resto. En su lógica primitiva, dar su hijo en pago de la muerta era una solución. ¡Y eso lo pensaba él, que no sabía cómo se quiere a un hijo!... »Dos días después... me encontré con la noticia de que un muchacho de Moca había sorprendido a Quique Blanco durmiendo y le había destrozado la cabeza de un tiro con el revólver del propio muerto. Más tarde supe que habían paseado el cadáver por todos los pueblos del Cibao, para que la gente no creyera que seguía vivo.»1 Este cuento del ilustre escritor cibaeño Juan Bosch, uno de sus Cuentos escritos antes del exilio y por lo tanto antes de que llegara a ser presidente de la República Dominicana, nos recuerda que Dios sí dio a su Hijo en pago de la muerte que merecía cada uno de nosotros a causa de nuestro pecado, y que, a diferencia de lo que sucedió luego de que mataron a Quique Blanco, no había cadáver suyo que pudiera pasearse por los pueblos de Judea o de Galilea «para que la gente no creyera que seguía vivo». Porque Jesucristo resucitó,2 y hoy quiere que lo busquemos de todo corazón para que lleguemos a conocerlo en persona como Él realmente es, un Dios poderoso pero clemente y compasivo.3 Carlos ReyUn Mensaje a la Concienciawww.conciencia.net 1 Juan Bosch, «La verdad», Cuentos escritos antes del exilio (Santo Domingo: Edición Especial, 1974), pp. 38‑47. 2 Jn 3:16‑17; Ro 4:25; 6:23; 1Co 15:3‑4 3 Éx 34:6; Neh 9:17; Sal 86:15

Por km2 y por población Haina que empezó ayer el velatorio de 21 ciudadanos y mantiene a tres desaparecidos es el municipio más afectado por el desastre de la discoteca Jet Set.Baní reporta doce decesos, Yaguate cinco, Moca tres…Institucionalmente el Banco Popular cinco decesos, el Reservas tres, el ADN dos muertes.Cito estos ejemplos porque no hay que repetir que esta tragedia ha tocado el país en pleno.Las autoridades informaron el cambio en el protocolo de búsqueda a rescate de cuerpos. Las declaraciones del ministro de salud a partir de los informes forenses es clara. La mayoría no sobrevivió a la lluvia de cemento e infraestructura pesada que les cayó encima. El trauma les produjo la muerte inmediata.Hay que reconocer el trabajo de las autoridades tanto en el operativo de rescate como en la organización para evitar la desinformación.La centralización de la data en el COE ha evitado la manipulación a pesar de eso la escoria mediática se esfuerza. Un articulo de diario libre al respecto dice que no se le puede pedir fragancia a la basura, porque solo hiede.El editorial de El Día, que ya les compartí en el canal de Whatsapp lo explica en 8 líneas “a medida que se diluía la intensidad de los trabajos de rescate, comenzaron a reaparecer los buscadores de «likes», incapaces de generar contenido con valor. Recurrieron entonces a la tergiversación, al sensacionalismo, a la invención y, sobre todo, al irrespeto a las víctimas, que no es otra cosa que revictimizarlas.Sin embargo, estos mercaderes del morbo no cargan solos con la culpa. También son responsables quienes los siguen, les comentan y, sobre todo, los premian con su aprobación digital. Mientras tengan audiencia, estas rapiñas seguirán haciendo daño, alimentadas por una sociedad que los legitima”.

Only two of them and they still managed to go on for 45 minutes?! Andrew and Martin talk polls, ethernet, guest appearances and then get deep on what things might be like if we started over. 'One Prime Plus Dot Com', the people shouted! Polls Have Consequences 00:00:00 The Poll from Episode 132 (https://social.lol/@hemisphericviews/114113731738388946)

What's good for the heart is good for the brain. Guest Brittany Butts, PhD, RN, describes helping patients understand this connection and implement actions to decrease their risk for both cardiovascular and cognitive declines. MMSE: https://muhc.ca/sites/default/files/micro/m-PT-OT/OT/Mini-Mental-State-Exam-%28MMSE%29.pdfMOCA: https://mocacognition.com/paper (official site)https://geriatrictoolkit.missouri.edu/cog/MoCA-8.3-English-Test-2018-04.pdf (PDF only)PCNA CE Course: Preventing Stroke: Applying the Guidelines https://pcna.net/online-course/preventing-stroke-applying-the-guidelines/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

¡Bienvenidos al único programa que te trae a los especímenes más brillantes del país! ¡Esto es otro gran episodio de Bájale 2! El doctor de la muerte existe y no te atrevas hacerle un corte de pastelillo porque te va a caer a tiro limpio y luego te hace un torniquete para salvarte. Suerte que el buen doctor no estará libre para encojonarse por el voceteo en la Parguera. Abuelas molestas que le caen a cantazo limpio a sus hermanas y criminales inteligentes de Moca, esto es mucho con demasiao en otro gran programa de Bájale 2. Grabado desde GW-Cinco Studio como parte de GW5 Network #tunuevatelevisión. Puedes ver toda la programación en www.gwcinco.com. siguenos en instagram @gw_cinco Patreon: patreon.com/gw5network patreon.com/hablandopop

Join us for a special edition of The Edge of Show, recorded live in Hong Kong at Consensus and Hack Season, where the future of Web3 is being shaped in real time. This episode is packed with insights from industry pioneers driving the next evolution of blockchain, tokenization, and decentralized finance. We sat down with some of the most influential voices in the space—Mark Mayerfeld, Chief Revenue Officer at GK by Galaxy, Patrick Schabhuttl, Head of Ecosystem at Mocaverse, Asaf Nadler, CEO and Co-Founder of Addressable, Jason Lau, CEO of OKX and Gleb Gora, CEO and Co-Founder of Vortex Foundation to uncover the latest innovations and challenges defining the industry today.In this episode, we explore:The tokenization of real-world assets and how stablecoins are evolving in institutional markets.Mocaverse's vision for Web3 identity with Moca 3.0, pushing for a more seamless, user-friendly decentralized experience.How AI-driven marketing and blockchain analytics are transforming how Web3 companies connect with the right users.OKX's European expansion and how they're bridging the gap between centralized and decentralized trading.Don't miss this deep dive into the technologies and strategies shaping the next era of Web3.Support us through our Sponsors! ☕

El 59.4% de la población tiene trabajo: InegiLey del ISSSTE busca beneficiar a maestros: Sheinbaum Empleados públicos en Argentina paran laboresMás información en nuestro podcast

Neuroscientist Adrian Owen discusses his KevinMD article, "A wake-up call for dementia detection: the urgent need for precision tools across health care." Adrian highlights the alarming rate of dementia diagnoses worldwide and examines the shortcomings of outdated detection tools like MMSE, SLUMS, and MoCA. He emphasizes the need for innovative, digitally-enabled cognitive assessment tools to ensure early and accurate diagnoses. The conversation explores actionable strategies to integrate advanced neuroscience into primary care, aiming to reduce health care costs and improve patient outcomes. Our presenting sponsor is DAX Copilot by Microsoft. Do you spend more time on administrative tasks like clinical documentation than you do with patients? You're not alone. Clinicians report spending up to two hours on administrative tasks for each hour of patient care. Microsoft is committed to helping clinicians restore the balance with DAX Copilot, an AI-powered, voice-enabled solution that automates clinical documentation and workflows. 70 percent of physicians who use DAX Copilot say it improves their work-life balance while reducing feelings of burnout and fatigue. Patients love it too! 93 percent of patients say their physician is more personable and conversational, and 75 percent of physicians say it improves patient experiences. Help restore your work-life balance with DAX Copilot, your AI assistant for automated clinical documentation and workflows. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://www.kevinmd.com/cme I'm partnering with Learner+ to offer clinicians access to an AI-powered reflective portfolio that rewards CME/CE credits from meaningful reflections. Find out more: https://www.kevinmd.com/learnerplus

Welcome to PsychEd, the psychiatry podcast for medical learners, by medical learners. This primer covers the differential diagnosis of dementia. Hosts: Dr. Alastair Morrison (PGY-1) and Dr. Angad Singh (PGY-1) Audio editing by: Dr. Angad Singh (PGY-1) Resources: MoCA: https://dementia.talkbank.org/protocol/materials/MOCA.pdf MMSE: https://meded.temertymedicine.utoronto.ca/sites/default/files/assets/resource/document/mini-mental-state-examinationmmse.pdf Beers Criteria: American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults PsychEd Episode 49: Dementia Assessment with Dr. Lesley Wiesenfeld References: American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596 Francis, J. & Young, B. (2022). Diagnosis of delirium and confusional states. UpToDate. Retrieved January 31, 2025, from https://www.uptodate.com/contents/delirium-and-acute-confusional-states-prevention-treatment-and-prognosis Larson, E. B. (2022). Evaluation of cognitive impairment and dementia. UpToDate. Retrieved January 31, 2025, from https://www.uptodate.com/contents/evaluation-of-cognitive-impairment-and-dementia PsychDB. (2022, Oct 3). Introduction to Dementia. Retrieved January 31, 2025, from https://www.psychdb.com/geri/dementia/home PsychDB. (2024, Feb 1). Delirium. Retrieved January 31, 2025, from https://www.psychdb.com/cl/1-delirium PsychDB. (2024, Feb 9). Alzheimer's Disease. Retrieved January 31, 2025, from https://www.psychdb.com/geri/dementia/alzheimers PsychDB. (2023, Oct 12). Vascular Dementia. Retrieved January 31, 2025, from https://www.psychdb.com/geri/dementia/vascular PsychDB. (2024, Jan 23). Frontotemporal Dementia. Retrieved January 31, 2025, from https://www.psychdb.com/geri/dementia/frontotemporal PsychDB. (2024, Feb 5). Dementia with Lewy Bodies. Retrieved January 31, 2025, from https://www.psychdb.com/geri/dementia/lewy-body For more PsychEd, follow us on Instagram (@psyched.podcast), Facebook (PsychEd Podcast), and X (@psychedpodcast). You can email us at psychedpodcast@gmail.com and visit our website at psychedpodcast.org.

Jon Jordan talks to Animoca Brands' chairman Yat Siu about the rise of memecoins, the value of Telegram and TON as a distribution platform, and how AI agents could shake everything up. [3:56] What's the state of memecoins in 2025? [6:28] "We are narrative, story-telling people - money, democracy, politics are all stories." [8:32] "The part that makes me a bit negative about memes is they are being abused by snipers." [11:02] Is PENGU a pure memecoin? Can a memecoin gain utility? [13:18] Will institutions buy memecoins? There will be memecoin ETFs. But this need narrative. [16:45] "Telegram is still the most powerful distribution platform." [20:50] "TON means that Telegram will survive [22:52] Ronin demonstrates the power of community as Axie was joined by Pixels. [23:22] "In web3, they came for the money but stayed for the social." [27:01] 'AI agents can now create tokens and pay humans to do things for it.' [28:31] How Yat deals with vampire agent IP attacks such AImonica and an AI Yat agent. [29:25] AI agents will make it easier for humans to interact with blockchains and wallets. [31:54] Yat's attitude to the AImonica AI agent project. [34:47] What's next for Mocaverse and the MOCA token? [36:15] Reputation systems don't have to just be for humans, but can be for AI agents too. [37:22] How blockchains and reputation can help student loans. [38:07] Why Animoca isn't as focused on building and investing games as it once was. [38:51] "We think NFTs are going to have a pretty big comeback in 2025."

Welcome to a very special episode of Moon to Moon. Our honored guest is Mother Witch Amanda Yates Garcia, also known as The Oracle of Los Angeles. Amanda has long been someone I deeply admire as a leader of integrity, honesty, wisdom, and inspiration. Amanda is incredibly smart, wildly magnetic, and wholly grounded in her devotion.  What happened here was a gift. And it's an honor to share this conversation with you today. May it be a lantern to light your heart and to lift your spirit.   Thank you, Amanda.  Amanda Yates Garcia is a writer, witch, and the Oracle of Los Angeles. Her work has been featured in The New York Times, The LA Times, The SF Chronicle, The London Times, CNN, BRAVO, as well as a viral appearance on FOX. She has led rituals, classes and workshops on magic and witchcraft at UCLA, UC Irvine, MOCA, The Hammer Museum, LACMA, The Getty and many other venues. Amanda hosts monthly moon rituals online, and the popular Between the Worlds podcast, which looks at the Western Mystery traditions through a mythopoetic lens. Her book, Initiated: Memoir of a Witch, received a starred review from Kirkus and Publisher's Weekly and has been translated into six languages. To find out more about her work become a member of her Mystery Cult on Substack.   +++ Learn more about The Magician's Table 2025 and find out who the 13th readers are here.  Applications open Feb 14 for Early Bird weekend (Feb 14-16).  To apply that weekend, you must be on the waitlist. Join the waitlist here. +++ E M E R G E N C E  A S T R O L O G Y ⁠⁠https://brittenlarue.com/ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠@brittenlarue ⁠⁠⁠⁠⁠⁠Order Living Astrology⁠⁠⁠⁠⁠⁠ Join my newsletter here Check out my new podcast CRYSTAL BALLERS on Spotify, Podbean, and Apple. +++ Podcast art: Angela George. Podcast music: Jonathan Koe.

Anti-amyloid therapies provide the first FDA-approved option to alter AD pathology, but an understanding of overall utility and value to patients remains in its infancy. In this episode, Teshamae Monteith, MD, FAAN, speaks with David S. Geldmacher, MD, FACP, FANA, author of the article “Treatment of Alzheimer Disease” in the Continuum® December 2024 Dementia issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Geldmacher is a professor and Warren Family Endowed Chair in Neurology and the director of the Division of Cognitive and Behavioral Neurology, Department of Neurology, Marnix E. Heersink School of Medicine at the University of Alabama at Birmingham in Birmingham, Alabama. Additional Resources Read the article: Treatment of Alzheimer Disease Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Transcript Full interview transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Monteith: This is Dr Teshamae Monteith. Today, I'm interviewing Dr David Geldmacher about his article on treatment of Alzheimer's disease, which appears in the December 2024 Continuum issue on dementia. Welcome to our podcast, Dr Geldmacher. How are you?  Dr Geldmacher: I'm very well, thank you. It's a pleasure to be here.  Dr Monteith: Yeah. So, why don't you introduce yourself to our audience? Dr Geldmacher: Sure. I'm David Geldmacher. I'm a professor of neurology at the University of Alabama in Birmingham and I lead the division of Cognitive and Behavioral Neurology.  Dr Monteith: So, I'm really excited about this, to personally learn, and I know that or neurology community is also really excited about this interview. So, why don't we start off with your main objective.  Dr Geldmacher: So, my main goal in the article was to review the FDA-approved pharmacologic treatments for dementia. There's lots of ways of thinking about treatment of dementia; psychosocial, caregiver support, and so forth. But I really wanted to focus on the issues of drug treatment because that's what has been our backbone for a long time and now has recently expanded.  Dr Monteith: Why don't we talk a little bit about, first of all, the boom in the field? What's that been like?  Dr Geldmacher: So, the big change in the field is over the last several years, we've had treatments become available that actually attack the underlying Alzheimer pathology, and that's new and different. For decades, we've been able to treat the symptoms of the disease, but this is the first time we've really been able to get to the root of the pathology and look toward removing amyloid plaques from the brain.  Dr Monteith: Let's step back a little bit and talk about the framework of diagnosis and how that leads into the therapeutic potential. I know you're going to dive into some of the biologics, but we should probably talk about the kind of holistic approach to considering the diagnosis. Dr Geldmacher: Sure. So, you know, when someone comes to the clinic with memory complaints, our question we have to ask is, is this neurologic origin, a structural origin like Alzheimer's disease or vascular dementia? Are there complicating factors, the software issues of mood disorders and sleep disorders and pain that can all magnify those symptoms? The clinical reasoning is a critical part of that, but in Alzheimer's disease, typically the problems revolve around difficulty forming new memories of events and activities, the episodic memory. And then it's often accompanied by changes in word finding and semantic knowledge. And those are the things that we look for in the clinic to really point toward an AD diagnosis. And then we support it with exclusion of other causes through blood work and identification of patterns of brain atrophy on MRI. And then most recently in the last couple of years, we've been able to add to that molecular imaging for amyloid with PET scans as well as, most recently, blood-based biomarkers for Alzheimer's pathology. So, it's really been a revolution in the diagnosis over these last several years.  Dr Monteith: And when approaching patients or populations of individuals, there seems to be a real full spectrum with looking at the societal burden, the biological impact, of course, risk factors of primary prevention, and now this whole area of brain health and secondary prevention. How do you kind of tie all of this together when talking to patients and family members?  Dr Geldmacher: Sure. So, the approaches for brain health apply to everyone. In basically every clinic visited, our brain aging and memory clinic, we reviewed lifestyle approaches to brain health like regular physical exercise, healthy diet, cognitive and social stimulation. And those are fundamental to the approach to everyone, whether they have cognitive impairments that are measurable or not. These are all things that are good for our brain health. And then, you know, focusing on the vascular risk factors in particular and working with the patient and their primary care team to ensure that lipids and blood sugar and blood pressure are all in good healthy ranges and being appropriately treated.  Dr Monteith: You know, there's this kind of whole considerations of clinically meaningful endpoints and clinical trials, and even when we're talking to our patients. What would you say the field has kind of identified has the best endpoints in helping patients? Would you call it impaired daily function? Is that like the best hard endpoint? Obviously, there are other things such as caregiver burden, but you know, how do you approach assessing patients? Dr Geldmacher: Defining the endpoints is very difficult. Typically, if we talk to patients and their families, they would like to have better memory or improve memory. How that applies in everyday life actually is daily function. And so, we focus very much on daily function. And when I talk about our therapies, whether they're symptomatic therapies or the new disease-modifying therapies, I really talk about maintenance of function and delays and decline or slowing of decline, helping to foster the person's independence in the activities that they have and be able to sustain that over the longer term.  Dr Monteith: And when thinking about diagnosis- and we're going to get into treatments, but when thinking about the diagnosis, and of course, it's full-spectrum from mild cognitive impairment to moderate and severe forms of dementia, but who should have CSF testing and PET imaging? Obviously, these are invasive, somewhat invasive and expensive tests. Should all people that walk in the door that have memory complaints? How do you stratify who should have tests? Dr Geldmacher: I think about this in a big funnel, basically, and the starting point of the funnel, of course, is the person with memory complaints. Then there's that neurologic reasoning. Are these memory complaints consistent with what we expect from the anatomy of Alzheimer's disease, with atrophy in in the hippocampus and temporal lobe? Do they have episodic memory loss or not? That first step is really trying to characterize, do the clinical patterns act like those of Alzheimer's disease or not? And then we follow the Academy of Neurology guidelines, looking for reversible sources of cognitive decline, things like B12 deficiency and depression, sleep disorders and the like, and try to exclude those. We start with structural imaging with everyone, and MRI, typically, that will help us understand vascular burden and patterns of atrophy, looking for things like mesial temporal atrophy or precuneus atrophy that are characteristic of Alzheimer's disease. If those things are all pointing in the direction of AD as opposed to something else, then typically before moving on to CSF or PET scan, we will use blood-based biomarkers, which are one of the big changes in the field in the last year or so, and there are now multiple panels of these available. The downside is they are typically not covered by insurance. On the other hand, they can really help us identify who is likely to have a positive PET scan or positive findings on CSF. We start to provide that counseling and information to the patient before they get to those more definitive tests. We can push people in the other direction. We can say, your blood-based biomarkers are negative or do not indicate AD as the most likely source of your condition now, so let's treat other things. Let's see what else we can focus on. The blood-based biomarkers are now, in our clinic at least, the critical choke point between the routine workout that we've always done on everyone and then the more advanced workup of proving amyloid pathology with CSF or a PET scan. Dr Monteith: How sensitive are those blood biomarkers and how early are they positive?  Dr Geldmacher: The sensitivity is generally pretty good, in the ninety plus percent range on average and it depends on which panel. And as you point out, when in the course of symptoms that they're done, we know that they become positive and presymptomatic or asymptomatic people. We're using these kinds of markers to screen people for prevention trials. So, I think when someone is symptomatic, they're a good indicator of the presence or absence of AD pathology. Now that doesn't mean the AD pathology is the sole cause of their symptoms. And so, we still need to think about those other things like sleep and mood and so forth. But they do point us in the in the direction of Alzheimer's change.  Dr Monteith: So why don't we talk about some of the more standard older treatments, and it's also important to leave with kind of some rational approach to when we start and what should we be counseling our patients on. So why don't we start with the older, you know, choline esterase inhibitors and then some of the MDA- I guess there's only one modulator, SEPTA modulator. Dr Geldmacher: So, I've been really fortunate in my career span, the time from the first of those symptomatic agents reaching the market in 1993 to seeing the disease modifying drugs enter the market now. I think most neurologists actually have entered practice after those clinical trials of the colon esterase inhibitors were published. So, one of my goals in this article was to review that primary data and what can we expect from those symptomatic drugs. We know that they are inconsistently effective in mild cognitive impairment, and the Academy of Neurology guidelines says there is not strong evidence to use them in mild cognitive impairment. But in mild AD and beyond, the cholinesterase inhibitors provide meaningful benefits. They delay decline, they can delay nursing home placement. They reduce overall costs of care. So, I think they provide real value. So, in the article I have reviewed what the data looked like on those. My approach is to start with oral Donepezil at five milligrams and increase it to ten in everyone who tolerates the five. If for whatever reason the oral Donepezil is not well tolerated, I'll switch to transdermal rivastigmine to help improve tolerability. There are very few head to head comparisons, but nothing suggests that one of the cholinesterase inhibitors is superior to the other for clinical outcomes, and there's no evidence to support conjoint use of more than one at a time. Should someone be showing decline then on typical cholinesterase inhibitor therapy - and people will, it's often delayed, but the decline will reemerge - then I will add the NMDA receptor, a modulator memantine and titrate that up to full dosing, either 10 mg twice a day for the conventional release or 22 mg extended release. And at that point we're sort of on maximal pharmacologic therapy for Alzheimer's disease. These agents can provide some benefit in other conditions, they're off-label except for Lewy body disease where rivastigmine is labeled. But they can provide benefit across different conditions. And there's some preliminary data, for instance, of acetylcholinesterase inhibitors being helpful in vascular cognitive impairment. So, I will use them, but I expect the greatest response when someone really does follow the patterns of Alzheimer's disease.  Dr Monteith: And you have a great chart, by the way, and nice figures looking at some of the meta-analyses on cognitive outcomes as well as functional outcomes. So, thank you for that.  Dr Geldmacher: In general, all of those tables favor treatment over placebo in the domains of cognition, daily function, neuropsychiatric symptoms. And it's that consistency of result that lets me know that we really are seeing a drug effect, that it's not a class effect with those, that we really are helping our patients. It's not like some studies are positive and some are negative. They are very consistently positive. Small magnitude, but consistently positive.  Dr Monteith: And I know we have a lot of patients coming in where, at least, their caregivers are complaining about agitation, and sleep is also a problem for others. And so how do you help that patient? I know you have a good algorithm that also you included in your article, but why don't you summarize how we should approach these symptoms? Dr Geldmacher: Sure. So, for nonpsychotic agitation, you know, just restlessness, wandering, pacing and so forth, my first choice is an off-label use of citalopram. And there is good clinical trials evidence to support that. if someone has psychotic agitation that is with delusions or hallucinations and so forth, I think we do need to move to the antipsychotic drugs. And the one drug that is now approved for treatment of agitation and Alzheimer's disease does fall into that antipsychotic category, along with its various black box warnings - and that's brexpiprazole. For many of our patients, getting coverage for that agent is difficult. It's not on many formularies. So, it is something I progress toward rather than start with. Similarly, for sleep, there is one approved agent for sleep, that's a dual orexin agonist. And it shows effectiveness, but can have some negative cognitive effects, and so I tend not to start with that either. My first choice when sleep is the primary issue for our patients with dementia is trazodone, and there are some small, limited studies for it's off-label used to enhance sleep. It's safe, inexpensive, often effective, and therefore it's my first choice. Dr Monteith: So, now let's get into the big conversations that everyone is having. Let's talk about the newer disease modifying anti amyloid therapies. Give us a summary dating back 2021 probably, although we can hold the preclinical work, but let's talk about what is available to our patients. Dr Geldmacher: Sure. And the development of anti-amyloid therapies goes all the way back to 1999. So, it's a pretty long course to get us to where we are today.  Dr Monteith: Yeah, that's why we limited that.  Dr Geldmacher: With that first approved agent with aducanumab in 2021, it received a limited or accelerated approval in FDA parlance. These agents, the aducanumab, lecanemab and donanemab, all approved, are known to remove amyloid pathology from the brain as measured by CSF and/or BIPET. They are amyloid lowering therapies, often called disease-modifying therapies. And across the agents there's some variable results. But if we look at the two with full approval, lecanemab and donanemab, they slow clinical progression by 25% to 35% on average. And that's measured by either cognitive measures or global measures or composite measures, but it's pretty consistent in that range of about one-third slowing. That makes it really difficult to discern in an individual patient, though, because there's so much variability in the progression of the disease already that it can be difficult to tell in one person that these drugs are working. They're also complex to use, so there's a qualification process that involves MRI to exclude things like a high tendency toward hemorrhage. It includes genetic testing for papal E4 status to help us understand the risk for complication, and then once-monthly or twice-monthly infusions with standardized schedule for MRI scanning. So, there's a lot that goes into managing these agents. And they are expensive, and we don't yet know their cost effectiveness. The cost effectiveness of the cholinesterase inhibitors was questioned when they first came out back in the 1990s, and it took five or ten years to really understand that they provided benefit to society and to individuals in those domains of quality of life and return on investment. And we're still learning about that with the disease modifying therapies.  Dr Monteith: So, two questions. One, the case that you presented was an individual having symptoms and kind of voiced their desire to be on these therapies. So, people are going to be asking, coming to clinic asking and then of course, they're going to be people that you select out. So, how do you make that decision to recommend this treatment for patients given the potential risk? Dr Geldmacher: We've got some really good guidance from appropriate use recommendation papers for aducanumab and lecanemab, and I'm expecting one from donanemab fairly soon. But the key is to identify individualized risks, and that involves knowing their APOE4 status, knowing their- whether they've had microhemorrhages in the brain previously, and then documenting that they really do have amyloid pathology with something like PET scan to establish those baselines. I talk to people about the burden of twice-monthly infusions or, now with donanemab, once-monthly infusions. And for instance, for someone who's got a working caregiver, getting to an infusion center twice a month can be a significant burden. And then if there are complications, frequent MRI scans and so forth. So, we talk about the burden of entering into this therapeutic pathway. The reality is that people who are qualified generally want it. I have relatively few folks who have said, no, these risks are more than I'm willing to accept. For decades my patients have said, anything you can do to slow this down, I'm willing to try. And now we're seeing that translated to reality with people willing to accept high-risk, high-cost treatments with the chance of slowing their individual progression.  Dr Monteith: And how do you select between the two treatments? Dr Geldmacher: So far that's been easy because donanemab's not readily available.  Dr Monteith: Outside of clinical trials, right?  Dr Geldmacher: Exactly. For prescription use, it's coming in - the first cases have now been infused - but it's not generally available. Nonetheless, what I will do for patients in this is look at the risk tables. So donanemab appears to have in general some higher rates of the Aria complications, amyloid-related imaging anomalies, and some people are going to be more risk tolerant of that for the payoff of potentially faster response. The donanemab trials restructured that. They did their first assessment of effectiveness. I had amyloid removal at six months and a significant proportion of people were eligible to discontinue treatment at six months because their amyloid was below treatable thresholds. So higher risk, perhaps faster action and fewer infusions for donanemab. Lecanemab we have more direct experience with, and between the two of them, the eighteen month outcomes are pretty much the same and indistinguishable. So are we in it for a quick hit, or are we in it for the long race? And different patients and different families will have differing opinions on where they want to accept that risk and burden and so forth. But so far, the data don't indicate a lot of difference in their longer-term outcomes. We still have plenty to learn.  Dr Monteith: And so, it sounds like, as you mentioned, we're looking at eighteen months out for kind of a hard outcome, and that there is a lot of variability in response rate. How are you tracking patients- you know about the imaging, so just in terms of clinical outcomes and efficacy?  Dr Geldmacher: Sure. So, for Medicare to reimburse on these treatments, people need to be enrolled in a registry program - and there are several of these, CMS runs one of their own. But the requirement for that is, every six months, to do cognitive and functional outcomes through the first two years. Cognitive outcomes are up to the clinician, but things like the mini mental state exam, the MoCA, are appropriate. In our own program, we use something we developed locally called the Alabama Brief Cognitive Screener. As for the cognitive outcomes and then for functional, we use an instrument called the General Activities of Daily Living Scale, but there are many other ADL scales that could be used as well. CMS does not mandate specific tests. Since the progression of the disease is variable to begin with, we don't really know how to interpret these results in reference to whether the drug is working, but I can tell a patient or a family member, your scores are stable, or, you have a decline of three points in this test. That's typical for this duration of illness. But there isn't a good way to know whether the drug is working in this person at this time, at least with our current levels of data.  Dr Monteith: So, I think we have to talk about health equity, and it sounds like Medicare is reimbursing for some of us. We look at different socioeconomic backgrounds, educational backgrounds, race, ethnicity. Not everyone is aware of these treatments. So, how do we get more patients to become aware of these treatments? And how do we get them to more people to help people? Dr Geldmacher: Yeah, I mean, that's- it's a major, major issue of inequity in our population. We've done some work at UAB looking at the flow of members of minority communities into memory clinics. So, we know that the overall population of, and I'll choose, for an example, blacks and African Americans, that they are represented a much higher rate in our overall UAB treatment population than they are in our memory clinic population. So, they're not even getting to us in the specialty clinic at the same rates as other segments of our population. We also know that blacks and African Americans in our population are not receiving PET scans as often as the overall treatment population. So yes, there are real, real problems with access. There are cultural issues behind this as well. And in many communities, a change in cognition, a loss of memory is an expected part of the aging process rather than recognized as a disease. So, people who come to us from minority communities are often further along in the course of cognitive and functional decline and beyond the point where they might qualify for the disease-modifying therapies, where early AD is the sort of defining boundary. So, I think more awareness and more screening in primary care settings, perhaps more community outreach to let people know that changes in memory that affect daily function are not normal as part of the aging process and should be evaluated for intervention. So, there's lots of places in our healthcare community where we could foster better outreach, better knowledge to get more folks access to the medicines. And this is before we even get to cost. Dr Monteith: Yeah, yeah. And obviously, there's some stigma as well.  Dr Geldmacher: That's right.  Dr Monteith: Really recognizing what the issues are and diving and asking those questions and funding research that asks those questions, as you mentioned, is really important. And then you have also a nice area where, you know, looking on the impact of treatments on caregiver-related outcomes, and of course ultimately want to keep patients out of nursing homes and prevent death. And so, can you talk a little bit about that? And, you know, mainly the caregiver burden.  Dr Geldmacher: So, my research in that area goes back a long way now. But I learned early in the course of therapy that many times the outcome that the family is noticing for symptomatic therapies is not a change in the patient's memory per se, but that there is less work involved in the caregiving. Less time is spent in direct caregiving roles. The patient may shadow less and because they have better independent cognition. I remember one family member once told me, the medicine you started is a godsend because now I can go to the bathroom by myself and he's not pounding on the door saying where are you, where are you. He's able to recall long enough that I'm in the bathroom that I have that moment of privacy. That was very meaningful to me to hear that. So. Dr Monteith: Cool. So why don't you just help us wrap this up and just give us, like, three main takeaway points that we should be getting out of your article? Dr Geldmacher: The three points that I would emphasize from my article is that the symptomatic therapies provide meaningful benefits and measurable, consistent, meaningful benefits. The second is that those benefits extend beyond things like cognitive test scores and into things like caregiver well-being and maintenance of independence in the home environment. And the third is that the disease-modifying therapies are an exciting opportunity to modify the pathology, but we still are learning about their cost effectiveness and their long-term benefit both to individuals and to society. But the only way we're going to learn that is by using them. And that was the experience that we gained from the symptomatic therapies that took use in the community for years before we really began to understand their true value. Dr Monteith: Thank you. That was excellent. And I put you on the spot, too.  Dr Geldmacher: No problem.  Dr Monteith: Again, today I've been interviewing Dr David Geldmacher, whose article on treatment of Alzheimer's disease appears in the most recent issue of Continuum on Dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at contentpub.com/AudioCME. Thank you for listening to Continuum Audio.

Episode No. 688 features artist Sayre Gomez and curator Anna Katz.  Gomez is included in two of the season's major contemporary group shows: "The Living End: Painting and Other Technologies, 1970-2000," at the Museum of Contemporary Art Chicago, and "Ordinary People: Photorealism and the Work of Art since 1968" at the Museum of Contemporary Art, Los Angeles.   Gomez is a Los Angeles-based painter whose work uses hyperrealism to address current events and representation and visuality in US society.   Katz is the curator of "Ordinary People," which is at MOCA through May 4. The exhibition's fine catalogue was published by the museum and DelMonico Books. Amazon and Bookshop offer it for about $65.  "The Living End" was curated by Jamillah James, who discussed her exhibition on Episode No. 683. It is on view through March 16. The exhibition catalogue is available from the MCA for under $20. Instagram: Sayre Gomez, Anna Katz, Tyler Green.

Episode No. 685 features artist Vincent Valdez and curators Theresa Harlan and Drew Johnson. The Contemporary Arts Museum Houston is presenting "Vincent Valdez: Just a Dream..." the first major survey of Valdez's career. The exhibition, which features Valdez's work across media, reveals Valdez's construction of US national memory. It was co-curated by Patricia Restrepo and Denise Markonish. It's on view at CAMH through March 23, 2025, when it will travel to the Massachusetts Museum of Contemporary Art. A catalogue is forthcoming. Also, Valdez is included in "Ordinary People: Photorealism and the Work of Art since 1968" at the Museum of Contemporary Art, Los Angeles. The exhibition surveys post-war photorealism up to the present. It was curated by Anna Katz with Paula Kroll and is on view through May 4, 2025. MOCA and DelMonico Books published an excellent catalogue. Amazon and Bookshop offer it for $65. Harlan and Johnson are the curators of "Born of the Bear Dance: Dugan Aguilar's Photographs of Native California" at the Oakland Museum of California. It's on view through June 22, 2025. The exhibition surveys Aguilar's presentation of Native life and land, mostly between 1982 and 2018. The exhibition is OMCA's first presentation of Aguilar's work after the Aguilar's family gift of his archive to the museum in 2022. The show does not have a catalogue, but many of the works in the show are featured within Harlan's 2015 Aguilar monograph for Heyday Books, "She Sang Me a Good Luck Song."